Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

Torrent Outlook Muted On COVID-19, Regulatory Concerns

After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted by the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.

Commercial Sales & Earnings Coronavirus COVID-19

‘Business Unusual’: COVID-19 Brought Commercial Changes To Pharma And It May Stick

The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.

Business Strategies Coronavirus COVID-19 Telehealth

Companies

Set Alert for Companies

Latest From Companies

Pfizer Chief Calls Patent Pool ‘Nonsense’, Fears Tussle Over Vaccine

Pharma will oppose a patent pool, but the world still needs a way to guarantee fair access to COVID-19 vaccines.

Commercial Companies

Coronavirus Update: Novartis Joins Vaccine Efforts With Gene Therapy Approach

Having kept out of the race to develop a vaccine until now, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.

Companies Coronavirus COVID-19

ASCO 2020: AZ’s Tagrisso Sails Into Early-Stage NSCLC On ‘Momentous’ ADAURA Trial Data

A highly impressive improvement in disease-free survival in ADAURA is set to pitch AstraZeneca’s best-selling product into a new untapped market, early-stage EGFRm NSCLC, reaping a possible $3bn in extra sales.

Cancer Clinical Trials

Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1 Billion Vaccine Adjuvant Doses

Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.

Companies Coronavirus COVID-19

Job Cuts As Nordic Nanovector Extends Cash Runway

Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.

Commercial Companies

Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study

The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.

Clinical Trials Neurology
See All

Deals

Set Alert for Deals

Latest From Deals

Finance Watch: Investors Bet Billions On Big Biopharma Offerings

Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.

Financing Business Strategies

Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape

The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.

Deals Business Strategies

Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio

The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.

Deals ImmunoOncology

Tech Transfer Roundup: Hoth Teams With VCU On Therapy To Block COVID-19 Replication

Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.

Deals Coronavirus COVID-19

‘Friendly Breakup’: Sanofi And Regeneron Agree Equity Revamp

Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.

Companies Commercial

China Bioventures' Role In Virus Fight Helps Secure $721m In New Funding, Deals

Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.

Deals Financing
See All

Strategy

Set Alert for Strategy

Latest From Strategy

Sanofi Vaccines Chief Loew To Be Ipsen CEO

Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.

Leadership Strategy

US Phlow Model And Drug Nationalism: Do Indian Firms Need To Be Watchful?

The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market. 

Commercial Strategy

Novartis Oncology Head Discusses Cancer Care Challenge With COVID-19

Susanne Schaffert tells Scrip that policies of prioritizing coronavirus treatment to the detriment of cancer care was a worrying move that is negatively impacting survival and mortality.

Cancer Coronavirus COVID-19

Can Glenmark’s Triple Therapy Combo Move COPD Treatment Needle?

Glenmark rolls out three-in-one inhaler therapy for COPD in India and hopes to address challenges faced by patients suffering from the severe form of the disease. Some early physician outlook appears mixed for the new combination in a segment where leading respiratory player Cipla has an established product.

Commercial Strategy

Gilead Licensing Deal Expands Remdesivir Access, Capacity

Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.

Commercial Coronavirus COVID-19

Ferring's Microbiome Success Based On Much More Than Gut Instinct

"There's a lot of hope and hype still in the microbiome sphere," Ferring's president Per Falk tells Scrip, but the rewards could be considerable for companies that can deliver well-documented safety and efficacy data and do not take try to take shortcuts.

Leadership Infectious Diseases
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Novartis Targets Quick Launches For Zolgensma in Europe

The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.

Approvals Gene Therapy

FDA Approval Makes Deciphera’s Qinlock First Fourth-Line GIST Drug

Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.

Launches Approvals

AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure

AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.

Pricing Strategies Cardiovascular
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC

EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.

Approvals Europe

Shifting EU Treatment Paradigms In CLL

The CLL market segment in the EU will now include a first-line combination therapy of AbbVie’s venetoclax and Roche’s obinutuzumab, which has recently been approved by the European Commission.

Cancer Approvals

How Big Pharma Profits Stack Up Against Other Industries

Research published in JAMA shows that the pharmaceutical industry outpaces other industries in the S&P 500 on several measures of profitability. 

Pricing Debate Market Intelligence
See All
UsernamePublicRestriction

Register